Paper36915460
Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
Wan Y and 1 other. J Gastrointest Oncol, 2023. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report. Papers, record 36915460. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36915460
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References17
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26938715 | Novel anti-angiogenic therapeutic strategies in colorectal cancer. | Expert Opin Investig Drugs | 2016 | https://conductscience.org/library/papers/26938715 | PubMed |
| 2 | 35261903 | Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. | Transl Cancer Res | 2022 | https://conductscience.org/library/papers/35261903 | PubMed |
| 3 | 35557597 | Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study. | J Gastrointest Oncol | 2022 | https://conductscience.org/library/papers/35557597 | PubMed |
| 4 | 36530921 | Biomarkers in the development of individualized treatment regimens for colorectal cancer. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/36530921 | PubMed |
| 5 | 36307056 | Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2023 | https://conductscience.org/library/papers/36307056 | PubMed |
| 6 | 34109130 | Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review. | Front Oncol | 2021 | https://conductscience.org/library/papers/34109130 | PubMed |
| 7 | 31790382 | Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials. | Med Sci Monit | 2019 | https://conductscience.org/library/papers/31790382 | PubMed |
| 8 | 31496821 | Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. | Cancer Manag Res | 2019 | https://conductscience.org/library/papers/31496821 | PubMed |
| 9 | 19114685 | A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19114685 | PubMed |
| 10 | 31848739 | Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? | Int J Colorectal Dis | 2020 | https://conductscience.org/library/papers/31848739 | PubMed |
| 11 | 29946728 | Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. | JAMA | 2018 | https://conductscience.org/library/papers/29946728 | PubMed |
| 12 | 17876013 | Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17876013 | PubMed |
| 13 | 20530421 | Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. | Anticancer Res | 2010 | https://conductscience.org/library/papers/20530421 | PubMed |
| 14 | 23313143 | The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil. | Eur J Cancer | 2013 | https://conductscience.org/library/papers/23313143 | PubMed |
| 15 | 30651398 | S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. | Oncologist | 2019 | https://conductscience.org/library/papers/30651398 | PubMed |
| 16 | 33830591 | Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. | Oncologist | 2021 | https://conductscience.org/library/papers/33830591 | PubMed |
| 17 | 19196673 | Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19196673 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39352649 | Clinical research progress of fruquintinib in the treatment of malignant tumors. | Invest New Drugs | 2024 | https://conductscience.org/library/papers/39352649 | PubMed |
| 38756629 | Efficacy and safety of gemcitabine plus raltitrexed or S-1 versus standard third-line therapies in metastatic colorectal cancer: a retrospective cohort study. | J Gastrointest Oncol | 2024 | https://conductscience.org/library/papers/38756629 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36915460
GET https://conductscience.org/api/papers/v1/36915460/authors